Single User License
INR 134840
Site License
INR 269680
Corporate User License
INR 404520

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Metastatic Adenocarcinoma of The Pancreas-Pipeline Review, H1 2015

Metastatic Adenocarcinoma of The Pancreas-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Metastatic Adenocarcinoma of The Pancreas-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Metastatic Adenocarcinoma of The Pancreas-Pipeline Review, H1 2015', provides an overview of the Metastatic Adenocarcinoma of The Pancreas's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Adenocarcinoma of The Pancreas, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Adenocarcinoma of The Pancreas and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Metastatic Adenocarcinoma of The Pancreas

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Metastatic Adenocarcinoma of The Pancreas and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Metastatic Adenocarcinoma of The Pancreas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Metastatic Adenocarcinoma of The Pancreas pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Metastatic Adenocarcinoma of The Pancreas

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Metastatic Adenocarcinoma of The Pancreas pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Metastatic Adenocarcinoma of The Pancreas Overview 9

Therapeutics Development 10

Pipeline Products for Metastatic Adenocarcinoma of The Pancreas-Overview 10

Pipeline Products for Metastatic Adenocarcinoma of The Pancreas-Comparative Analysis 11

Metastatic Adenocarcinoma of The Pancreas-Therapeutics under Development by Companies 12

Metastatic Adenocarcinoma of The Pancreas-Therapeutics under Investigation by Universities/Institutes 15

Metastatic Adenocarcinoma of The Pancreas-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Metastatic Adenocarcinoma of The Pancreas-Products under Development by Companies 18

Metastatic Adenocarcinoma of The Pancreas-Products under Investigation by Universities/Institutes 20

Metastatic Adenocarcinoma of The Pancreas-Companies Involved in Therapeutics Development 21

Aduro BioTech, Inc. 21

Amgen Inc. 22

Axcentua Pharmaceuticals AB 23

BioCancell Therapeutics, Inc. 24

Boehringer Ingelheim GmbH 25

Boston Biomedical, Inc. 26

Eleison Pharmaceuticals, Inc. 27

Gilead Sciences, Inc. 28

Halozyme Therapeutics, Inc. 29

Incyte Corporation 30

Millennium Pharmaceuticals, Inc. 31

Nanotherapeutics, Inc. 32

NewLink Genetics Corporation 33

Novartis AG 34

Phoenix Biotechnology, Inc. 35

Sanofi 36

Teva Pharmaceutical Industries Limited 37

Threshold Pharmaceuticals, Inc. 38

Metastatic Adenocarcinoma of The Pancreas-Therapeutics Assessment 39

Assessment by Monotherapy Products 39

Assessment by Target 40

Assessment by Mechanism of Action 42

Assessment by Route of Administration 44

Assessment by Molecule Type 46

Drug Profiles 48

AXP-10711-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

BBI-608-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

BC-819-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

BI-853520-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

binimetinib-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

CEP-37250-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

CRS-207-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

Dendritic Cell Therapy for Cancer-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

erismodegib-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

evofosfamide-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

ganitumab-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

glufosfamide-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

indoximod-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

LGK-974-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

MesoCART-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

MLN-0264-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

paclitaxel lipsomal-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

PBI-05204-Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

PEGPH-20-Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

plerixafor-Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

PRI-724-Drug Profile 91

Product Description 91

Mechanism of Action 91

R&D Progress 91

ruxolitinib phosphate-Drug Profile 93

Product Description 93

Mechanism of Action 93

R&D Progress 93

SiG12D-LODER-Drug Profile 98

Product Description 98

Mechanism of Action 98

R&D Progress 98

simtuzumab-Drug Profile 100

Product Description 100

Mechanism of Action 100

R&D Progress 100

Stem Cell Therapy for Oncology-Drug Profile 102

Product Description 102

Mechanism of Action 102

R&D Progress 102

Triapine-Drug Profile 103

Product Description 103

Mechanism of Action 103

R&D Progress 103

Metastatic Adenocarcinoma of The Pancreas-Recent Pipeline Updates 105

Metastatic Adenocarcinoma of The Pancreas-Dormant Projects 141

Metastatic Adenocarcinoma of The Pancreas-Discontinued Products 142

Metastatic Adenocarcinoma of The Pancreas-Product Development Milestones 143

Featured News & Press Releases 143

Nov 03, 2014: Threshold Pharmaceuticals' Partner Merck KGaA Completes Target Enrollment in the TH-302 Phase 3 MAESTRO Study in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma 143

Appendix 144

Methodology 144

Coverage 144

Secondary Research 144

Primary Research 144

Expert Panel Validation 144

Contact Us 144

Disclaimer 145

List of Tables

Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas, H1 2015 10

Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 13

Number of Products under Development by Companies, H1 2015 (Contd..1) 14

Number of Products under Investigation by Universities/Institutes, H1 2015 15

Comparative Analysis by Late Stage Development, H1 2015 16

Comparative Analysis by Clinical Stage Development, H1 2015 17

Products under Development by Companies, H1 2015 18

Products under Development by Companies, H1 2015 (Contd..1) 19

Products under Investigation by Universities/Institutes, H1 2015 20

Metastatic Adenocarcinoma of The Pancreas-Pipeline by Aduro BioTech, Inc., H1 2015 21

Metastatic Adenocarcinoma of The Pancreas-Pipeline by Amgen Inc., H1 2015 22

Metastatic Adenocarcinoma of The Pancreas-Pipeline by Axcentua Pharmaceuticals AB, H1 2015 23

Metastatic Adenocarcinoma of The Pancreas-Pipeline by BioCancell Therapeutics, Inc., H1 2015 24

Metastatic Adenocarcinoma of The Pancreas-Pipeline by Boehringer Ingelheim GmbH, H1 2015 25

Metastatic Adenocarcinoma of The Pancreas-Pipeline by Boston Biomedical, Inc., H1 2015 26

Metastatic Adenocarcinoma of The Pancreas-Pipeline by Eleison Pharmaceuticals, Inc., H1 2015 27

Metastatic Adenocarcinoma of The Pancreas-Pipeline by Gilead Sciences, Inc., H1 2015 28

Metastatic Adenocarcinoma of The Pancreas-Pipeline by Halozyme Therapeutics, Inc., H1 2015 29

Metastatic Adenocarcinoma of The Pancreas-Pipeline by Incyte Corporation, H1 2015 30

Metastatic Adenocarcinoma of The Pancreas-Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 31

Metastatic Adenocarcinoma of The Pancreas-Pipeline by Nanotherapeutics, Inc., H1 2015 32

Metastatic Adenocarcinoma of The Pancreas-Pipeline by NewLink Genetics Corporation, H1 2015 33

Metastatic Adenocarcinoma of The Pancreas-Pipeline by Novartis AG, H1 2015 34

Metastatic Adenocarcinoma of The Pancreas-Pipeline by Phoenix Biotechnology, Inc., H1 2015 35

Metastatic Adenocarcinoma of The Pancreas-Pipeline by Sanofi, H1 2015 36

Metastatic Adenocarcinoma of The Pancreas-Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 37

Metastatic Adenocarcinoma of The Pancreas-Pipeline by Threshold Pharmaceuticals, Inc., H1 2015 38

Assessment by Monotherapy Products, H1 2015 39

Number of Products by Stage and Target, H1 2015 41

Number of Products by Stage and Mechanism of Action, H1 2015 43

Number of Products by Stage and Route of Administration, H1 2015 45

Number of Products by Stage and Molecule Type, H1 2015 47

Metastatic Adenocarcinoma of The Pancreas Therapeutics-Recent Pipeline Updates, H1 2015 105

Metastatic Adenocarcinoma of The Pancreas-Dormant Projects, H1 2015 141

Metastatic Adenocarcinoma of The Pancreas-Discontinued Products, H1 2015 142

List of Figures

Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas, H1 2015 10

Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 17

Assessment by Monotherapy Products, H1 2015 39

Number of Products by Top 10 Targets, H1 2015 40

Number of Products by Stage and Top 10 Targets, H1 2015 40

Number of Products by Top 10 Mechanism of Actions, H1 2015 42

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 42

Number of Products by Top 10 Routes of Administration, H1 2015 44

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 44

Number of Products by Top 10 Molecule Types, H1 2015 46

Number of Products by Stage and Top 10 Molecule Types, H1 2015 46

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Aduro BioTech, Inc.

Amgen Inc.

Axcentua Pharmaceuticals AB

BioCancell Therapeutics, Inc.

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

Eleison Pharmaceuticals, Inc.

Gilead Sciences, Inc.

Halozyme Therapeutics, Inc.

Incyte Corporation

Millennium Pharmaceuticals, Inc.

Nanotherapeutics, Inc.

NewLink Genetics Corporation

Novartis AG

Phoenix Biotechnology, Inc.

Sanofi

Teva Pharmaceutical Industries Limited

Threshold Pharmaceuticals, Inc.

Metastatic Adenocarcinoma of The Pancreas Therapeutic Products under Development, Key Players in Metastatic Adenocarcinoma of The Pancreas Therapeutics, Metastatic Adenocarcinoma of The Pancreas Pipeline Overview, Metastatic Adenocarcinoma of The Pancreas Pipeline, Metastatic Adenocarcinoma of The Pancreas Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com